Renamed, common liver diseases might get fairer shake at treatment, researchers hope
A slate of liver diseases got a rebrand this year. Experts hope the change can generate more conversation — and research interest — for conditions that still lack treatments.
A group of over 200 physicians, public health experts, industry representatives, regulatory officials, and patient advocates made the call in a supermajority vote: Non-alcoholic fatty liver disease, or NAFLD, would be renamed metabolic dysfunction-associated steatotic liver disease. MASLD for short (pronounced MAA-zuld).
